News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Swedish Pharmaceutical Company Medivir AB (MVRBF) Chooses Certara Corporation’s D360 As Its Global Drug Discovery Platform


1/27/2014 9:34:46 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. LOUIS--(BUSINESS WIRE)--Certara™, a leading provider of software and scientific consulting services to improve productivity and decision-making from drug discovery through drug development, today announced that Medivir AB, a Swedish pharmaceutical company that focuses on infectious diseases including hepatitis C, has selected D360 as its global drug discovery platform. Certara’s D360 is an integrated solution for the query, analysis and visualization of drug discovery and development data. Medivir will use D360 to deliver research data and analytic tools to its discovery chemists and biologists in Stockholm, Sweden, and Cambridge, UK. The information will be sourced from its existing repository of chemical structure and biological assay data.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES